• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc. (Amendment)

    2/14/24 2:06:57 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGIO alert in real time by email
    SC 13G/A 1 rocksprings-agio123123a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    AGIOS PHARMACEUTICALS, INC.

    (Name of Issuer)

     

    Common Stock, Par Value $0.001 per share

    (Title of Class of Securities)

     

    00847X104

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  00847X104
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital Management LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,152,173
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,152,173
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,152,173
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    3.85%
    12
    TYPE OF REPORTING PERSON
     
    IA

     

     


     

    CUSIP No.  00847X104
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Rock Springs Capital LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,152,173
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,152,173
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,152,173
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    3.85%
    12
    TYPE OF REPORTING PERSON
     
    OO; HC

     

     
     

     

    CUSIP No.  00847X104
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    AGIOS PHARMACEUTICALS, INC. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices

    88 Sidney Street

    Cambridge, MA 02139

    Item 2.(a) Name of Person Filing

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

     

    i. Rock Springs Capital Management LP (“RSCM”);

    ii. Rock Springs Capital LLC (“RSC”)

    This Statement relates to Shares (as defined herein) held directly by Rock Springs Capital Master Fund LP (“Master Fund”), which is a Cayman Island exempted limited partnership, and Four Pines Master Fund LP (“Four Pines”), which is a Cayman Islands exempted limited partnership, and indirectly held by RSCM, a Delaware limited partnership, and RSC, a Delaware limited liability company. RSCM serves as the investment manager to each of the Master Fund and Four Pines. RSC is the general partner of RSCM.

    (b) Address of Principal Business Office, or, if none, Residence

    Rock Springs Capital Management LP and Rock Springs Capital LLC

    650 South Exeter, Suite 1070

    Baltimore, MD 21202

     

     

    (c) Citizenship

    Rock Springs Capital Management LP - Delaware

    Rock Springs Capital LLC - Delaware

     (d) Title of Class of Securities

    Common Stock, Par Value $0.001 per share (the “Shares”)

     (e) CUSIP No.:

    00847X104

     
     

     

    CUSIP No.  00847X104
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

     
     

     

    CUSIP No. 00847X104
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    As of the date of this filing, the Reporting Persons may be deemed to be the beneficial owners of 2,152,173 Shares, which amount includes 1,900,000 Shares directly beneficially owned by the Master Fund, and 252,173 Shares directly beneficially owned by Four Pines. The percent of class is determined by dividing the number of Shares beneficially owned by the Reporting Persons by 55,891,284 as reported on the Issuer’s Form 10-Q filed on November 2, 2023.

    (a) Amount beneficially owned:

    Rock Springs Capital Management LP: 2,151,814

    Rock Springs Capital LLC: 2,151,814

     

    (b) Percent of class:

    Rock Springs Capital Management LP: 3.85%

    Rock Springs Capital LLC: 3.85%

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

     

    (ii) Shared power to vote or to direct the vote:

    Rock Springs Capital Management LP: 2,151,814

    Rock Springs Capital LLC: 2,151,814

     

    (iii) Sole power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 0

    Rock Springs Capital LLC: 0

     

    (iv) Shared power to dispose or to direct the disposition of:

    Rock Springs Capital Management LP: 2,151,814

    Rock Springs Capital LLC: 2,151,814

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

     

    See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

     

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Please see response to Item 2.

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than the activities solely in connection with a nomination under §240.14a-11.

     

     

     
     
    CUSIP No.  20454B104
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title: Member

     

       

     

     

     
     
    CUSIP No. 20454B104
     SCHEDULE 13G
    Page 8 of 8 Pages

     

     

    JOINT FILING AGREEMENT

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Date: February 14, 2024

     

     

     

    Rock Springs Capital Management LP

    By: Rock Springs Capital LLC, General Partner 

           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

      Rock Springs Capital LLC
           
      By:   Graham McPhail
        Name:  Graham McPhail 
        Title:  Member

     

     

     

     

     

     

     

     

    Get the next $AGIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGIO

    DatePrice TargetRatingAnalyst
    11/20/2025$34.00Market Perform → Outperform
    Leerink Partners
    11/19/2025$28.00Outperform → Sector Perform
    RBC Capital Mkts
    2/24/2025$58.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    10/10/2024$51.00Outperform
    Raymond James
    9/27/2024$60.00 → $56.00Outperform → Market Perform
    Leerink Partners
    2/8/2024Overweight
    Cantor Fitzgerald
    2/3/2023$41.00Overweight
    Piper Sandler
    More analyst ratings

    $AGIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PYRUKYND issued to AGIOS PHARMACEUTICALS INC

    Submission status for AGIOS PHARMACEUTICALS INC's drug PYRUKYND (ORIG-1) with active ingredient MITAPIVAT has changed to 'Approval' on 02/17/2022. Application Category: NDA, Application Number: 216196, Application Classification: Type 1 - New Molecular Entity

    2/17/22 2:39:08 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TIBSOVO issued to AGIOS PHARMS INC

    Submission status for AGIOS PHARMS INC's drug TIBSOVO (SUPPL-7) with active ingredient IVOSIDENIB has changed to 'Approval' on 03/18/2021. Application Category: NDA, Application Number: 211192, Application Classification: Labeling

    3/22/21 5:06:31 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scadden David exercised 200 shares at a strike of $18.09 and sold $8,768 worth of shares (200 units at $43.84) (SEC Form 4)

    4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

    11/14/25 4:04:55 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Gheuens Sarah exercised 2,454 shares at a strike of $25.01 and sold $107,436 worth of shares (2,454 units at $43.78) (SEC Form 4)

    4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

    11/13/25 4:08:59 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Gheuens Sarah exercised 200 shares at a strike of $25.01 and sold $8,762 worth of shares (200 units at $43.81) (SEC Form 4)

    4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

    11/3/25 4:10:51 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agios Pharma upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Agios Pharma from Market Perform to Outperform and set a new price target of $34.00

    11/20/25 7:56:46 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Agios Pharma from Outperform to Sector Perform and set a new price target of $28.00

    11/19/25 12:52:13 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Agios Pharma with a new price target

    H.C. Wainwright initiated coverage of Agios Pharma with a rating of Buy and set a new price target of $58.00

    2/24/25 7:01:42 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

    Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did not meet statistical significance in primary endpoint of annualized rate of SCPCs (pain crises), and the key secondary endpoint of change from baseline in PROMIS Fatigue was not met Patients in the mitapivat arm who achieved hemoglobin response had clinically meaningful benefits in SCPC-related endpoints and PROMIS Fatigue Favorable safety profile observed in RISE UP Phase 3 trial was consistent with that observed in prior mitapivat sickle cell disease trials Company will share the comprehens

    11/19/25 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

    $12.9 million in third quarter PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch in 2026Phase 2b tebapivat trial in lower-risk MDS fully enrolled; topline results expected in early 2026$1.3 billion dollars in cash, cash equivalents and marketable securities as of September 30, 2025 CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused

    10/30/25 6:30:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

    Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP's opinion, with the final decision expected by early 2026 PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, pending European Commission approval Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on del

    10/17/25 8:15:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    SEC Filings

    View All

    SEC Form 10-Q filed by Agios Pharmaceuticals Inc.

    10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

    10/30/25 9:57:01 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

    10/30/25 6:32:30 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Agios Pharmaceuticals Inc.

    144 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    10/8/25 4:01:36 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    Leadership Updates

    Live Leadership Updates

    View All

    Agios Appoints Dr. Jay Backstrom to Board of Directors

    CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors, effective immediately. Dr. Backstrom is an accomplished healthcare executive with a proven track record of advancing clinical programs across a range of therapeutic areas, including rare diseases, to regulatory approval. "We are thrilled to welcome Jay to the Agios Board of Directors," said Brian Goff, Chief Executive Officer, Agios. "His deep scientific insight, extensive regulatory expertise, and s

    7/8/25 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

    Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development as Chief Business Officer of Agios Pharmaceuticals (NASDAQ:AGIO), and previously held strategic product and portfolio roles at Biogen (NASDAQ:BIIB). In her role at Cardurion, she will be responsible for leading corporate development, bus

    1/8/25 8:00:00 AM ET
    $AGIO
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Agios Appoints Catherine Owen to Board of Directors

    – John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Catherine Owen has been appointed to its board of directors, effective June 13, 2023. Agios also announced that, following a collaborative succession planning process, John Maraganore, Ph.D., who has served as a valuable board member and advisor to the company since 2011, will step down from the board of directors, effective immediately, and

    5/25/23 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    Financials

    Live finance-specific insights

    View All

    Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

    Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did not meet statistical significance in primary endpoint of annualized rate of SCPCs (pain crises), and the key secondary endpoint of change from baseline in PROMIS Fatigue was not met Patients in the mitapivat arm who achieved hemoglobin response had clinically meaningful benefits in SCPC-related endpoints and PROMIS Fatigue Favorable safety profile observed in RISE UP Phase 3 trial was consistent with that observed in prior mitapivat sickle cell disease trials Company will share the comprehens

    11/19/25 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

    $12.9 million in third quarter PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch in 2026Phase 2b tebapivat trial in lower-risk MDS fully enrolled; topline results expected in early 2026$1.3 billion dollars in cash, cash equivalents and marketable securities as of September 30, 2025 CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused

    10/30/25 6:30:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

    CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 30, 2025, at 8:00 a.m. ET to report its third quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company's website approximately two hours after the event. About Agios: Fueled by Connections

    10/16/25 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

    SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    11/14/24 3:44:53 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

    SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    11/8/24 2:40:47 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc. (Amendment)

    SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    2/14/24 2:21:13 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care